National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2019 (No. 1) (PB 4 of 2019) (Cth)

PB 4 of 2019

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2019 (No. 1)

National Health Act 1953

___________________________________________________________________________

I, BEN SLADIC, Assistant Secretary, Pharmacy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 100(2) of the National Health Act 1953.

Dated       29 January 2019

BEN SLADIC

Assistant Secretary

Pharmacy Branch

Technology Assessment and Access Division

Department of Health

___________________________________________________________________________

1. Name of Instrument

(1)This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2019 (No. 1).

(2)This Instrument may also be cited as PB 4 of 2019.

1. Commencement

This Instrument commences on 1 February 2019.

1. Amendment of National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011)

Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

Schedule 1       Amendments

1. Schedule 1, Part 1, entry for Docetaxel

omit:

Solution concentrate for I.V. infusion 20 mg in 2 mL Injection DBL Docetaxel Concentrated Injection PF MP D

1. Schedule 1, Part 1, entry for Fluorouracil in the form Injection 1000 mg in 20 mL

omit:

DBL Fluorouracil Injection BP PF MP C6266 C6297 D

1. Schedule 1, Part 1, entry for Gemcitabine

omit:

Solution for injection 200 mg (as hydrochloride) in 5.3 mL Injection DBL Gemcitabine Injection PF MP D

1. Schedule 1, Part 1, entry for Idarubicin in the form Solution for I.V. injection containing idarubicin hydrochloride 5 mg in 5 mL

omit:

Idarubicin Ebewe SZ MP C6247 PB

1. Schedule 1, Part 1, entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 50 mg in 10 mL

omit:

DBL Oxaliplatin Concentrate PF MP D

1. Schedule 1, Part 1, entry for Pemetrexed in each of the forms: Powder for I.V. infusion 100 mg (as disodium); Powder for I.V. infusion 500 mg (as disodium); and Powder for I.V. infusion 1 g (as disodium)

omit:

Pemetrexed MYX OC MP C4792 C7195 D

1. Schedule 1, Part 1, entry for Vinorelbine in each of the forms: Solution for I.V. infusion 10 mg (as tartrate) in 1 mL; and Solution for I.V. infusion 50 mg (as tartrate) in 5 mL

omit:

Hospira Pty Limited PF MP PB

1. Schedule 3, details relevant to Responsible Person code FB

omit from the column headed “Responsible Person”: Medicament